Candel Therapeutics Shares Fall Premarket After Public Offering

Dow Jones

Dec 13, 2024

By Colin Kellaher

Candel Therapeutics shares slid more than 30% in premarket trading Friday after the clinical-stage biopharmaceutical company took advantage of a surge in its stock price this week to raise $80 million in a public offering.

The Needham, Mass., company said it is selling more than 13.3 million shares and prefunded warrants at $6 apiece, 39% below Thursday's closing price of $9.80 but 30% above Tuesday's closing price of $4.61.

On Wednesday, Candel said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer, sending its share price soaring.

Shares were recently down 31% to $6.75 in premarket trading.

Candel, which had about 32.5 million shares outstanding as of Sept. 30, said it will use proceeds from the offering to continue the development of its product candidates, including preparing to file for Food and Drug Administration approval of submission CAN-2409 in prostate cancer.

The company said it expects the proceeds, coupled with its existing resources, to extend its runway into the first quarter of 2027.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 13, 2024 06:18 ET (11:18 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491538325"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491538325\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491538325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491538325","market":"fut","top_or_hot":-1,"title":"Candel Therapeutics Shares Fall Premarket After Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slid more than 30% in premarket trading Friday after the clinical-stage biopharmaceutical company took advantage of a surge in its stock price this week to raise $80 million in a public offering. \n</p>\n<p>\n  The Needham, Mass., company said it is selling more than 13.3 million shares and prefunded warrants at $6 apiece, 39% below Thursday's closing price of $9.80 but 30% above Tuesday's closing price of $4.61. \n</p>\n<p>\n  On Wednesday, Candel said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer, sending its share price soaring. \n</p>\n<p>\n  Shares were recently down 31% to $6.75 in premarket trading. \n</p>\n<p>\n  Candel, which had about 32.5 million shares outstanding as of Sept. 30, said it will use proceeds from the offering to continue the development of its product candidates, including preparing to file for Food and Drug Administration approval of submission CAN-2409 in prostate cancer. \n</p>\n<p>\n  The company said it expects the proceeds, coupled with its existing resources, to extend its runway into the first quarter of 2027. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 06:18 ET (11:18 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Shares Fall Premarket After Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Shares Fall Premarket After Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-13 19:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slid more than 30% in premarket trading Friday after the clinical-stage biopharmaceutical company took advantage of a surge in its stock price this week to raise $80 million in a public offering. \n</p>\n<p>\n  The Needham, Mass., company said it is selling more than 13.3 million shares and prefunded warrants at $6 apiece, 39% below Thursday's closing price of $9.80 but 30% above Tuesday's closing price of $4.61. \n</p>\n<p>\n  On Wednesday, Candel said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer, sending its share price soaring. \n</p>\n<p>\n  Shares were recently down 31% to $6.75 in premarket trading. \n</p>\n<p>\n  Candel, which had about 32.5 million shares outstanding as of Sept. 30, said it will use proceeds from the offering to continue the development of its product candidates, including preparing to file for Food and Drug Administration approval of submission CAN-2409 in prostate cancer. \n</p>\n<p>\n  The company said it expects the proceeds, coupled with its existing resources, to extend its runway into the first quarter of 2027. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 06:18 ET (11:18 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491538325","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491538325","pubTimestamp":1734088680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Candel Therapeutics shares slid more than 30% in premarket trading Friday after the clinical-stage biopharmaceutical company took advantage of a surge in its stock price this week to raise $80 million in a public offering.The Needham, Mass., company said it is selling more than 13.3 million shares and prefunded warrants at $6 apiece, 39% below Thursday's closing price of $9.80 but 30% above Tuesday's closing price of $4.61.On Wednesday, Candel said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer, sending its share price soaring.Shares were recently down 31% to $6.75 in premarket trading.Candel, which had about 32.5 million shares outstanding as of Sept. 30, said it will use proceeds from the offering to continue the development of its product candidates, including preparing to file for Food and Drug Administration approval of submission CAN-2409 in prostate cancer.The company said it expects the proceeds, coupled with its existing resources, to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","CADL":"Candel Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Candel Therapeutics公开募股后股价盘前下跌","themeId":"90afa6d46a880430caf68546577aba0f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CADL":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Candel Therapeutics shares slid more than 30% in premarket trading Friday after the clinical-stage biopharmaceutical company took advantage of a surge in its stock price this week to raise $80 million in a public offering. \n\n\n  The Needham, Mass., company said it is selling more than 13.3 million shares and prefunded warrants at $6 apiece, 39% below Thursday's closing price of $9.80 but 30% above Tuesday's closing price of $4.61. \n\n\n  On Wednesday, Candel said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer, sending its share price soaring. \n\n\n  Shares were recently down 31% to $6.75 in premarket trading. \n\n\n  Candel, which had about 32.5 million shares outstanding as of Sept. 30, said it will use proceeds from the offering to continue the development of its product candidates, including preparing to file for Food and Drug Administration approval of submission CAN-2409 in prostate cancer. \n\n\n  The company said it expects the proceeds, coupled with its existing resources, to extend its runway into the first quarter of 2027. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 06:18 ET (11:18 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}